Transdifferentiation

Transdifferentiation is the direct conversion of a cancer cell from one differentiated lineage identity to a distinct, different differentiated lineage identity, most clinically significant when occurring as an acquired mechanism of therapeutic resistance in which a tumor originally driven by and dependent on one cell-of-origin lineage program converts to an alternative lineage program no longer dependent on the original therapeutic target. It is distinguished from dedifferentiation, which involves regression toward a less mature state without necessarily adopting a specific alternative mature identity, by its defining outcome of arrival at a genuinely distinct, well-characterized differentiated cell type.

Neuroendocrine Transdifferentiation in Prostate Cancer

The most extensively characterized clinical example of therapy-induced transdifferentiation occurs in prostate cancer, in which adenocarcinoma cells originally dependent on androgen receptor signaling convert to a treatment-resistant neuroendocrine phenotype (termed treatment-emergent neuroendocrine prostate cancer) following prolonged androgen receptor pathway inhibition:

This transition is characterized molecularly by loss of androgen receptor pathway dependence and expression, concurrent loss of the tumor suppressors RB1 and TP53 (frequently through combined biallelic inactivation), and upregulation of neuroendocrine and neural lineage transcription factors including SOX2 and ASCL1, producing a tumor with a fundamentally altered dependency profile no longer sensitive to the androgen receptor-targeted therapy that originally drove the transition.

Neuroendocrine Transdifferentiation in Lung Cancer

A closely parallel phenomenon occurs in a subset of EGFR-mutant lung adenocarcinomas following prolonged EGFR tyrosine kinase inhibitor therapy, in which the tumor transforms histologically into small-cell lung carcinoma, a distinct, neuroendocrine-differentiated lung cancer subtype with fundamentally different treatment approaches and generally worse prognosis, while retaining the original activating EGFR mutation, directly demonstrating that the transdifferentiated tumor arises from the original adenocarcinoma clone through lineage switching rather than representing a genetically distinct, independently arising second malignancy.

Shared Molecular Basis Across Transdifferentiation Instances

Despite arising in different tissue contexts, the prostate and lung cancer neuroendocrine transdifferentiation phenomena share a substantially overlapping molecular basis, centered on combined RB1/TP53 loss functioning as a permissive gatekeeper event:

1. RB1/TP53 Co-Loss as an Enabling Event — Combined loss of both RB1 and TP53 tumor suppressor function removes critical restraints on cell cycle control and genomic and epigenomic stability, creating a permissive cellular context in which the extensive transcriptional reprogramming required for lineage switching becomes achievable, and clinical and experimental evidence indicates that RB1/TP53 co-loss substantially precedes and predicts subsequent neuroendocrine transdifferentiation.
2. SOX2-Driven Neural/Neuroendocrine Reprogramming — Upregulation of SOX2, alongside additional neuroendocrine lineage-specifying factors (including ASCL1), directly drives the transcriptional program establishing neuroendocrine identity, functioning here as the master regulator of the arrival lineage state in a manner directly analogous to the master regulator concept described for transcriptional state reprogramming generally.
3. Continued Therapy Pressure as the Selective Driver — In both contexts, transdifferentiation is understood to arise under sustained selective pressure from a therapy targeting the original lineage-defining dependency, functioning as an escape mechanism analogous in overall logic to the broader category of plasticity inducing signals, with the specific outcome (neuroendocrine identity) determined by the particular permissive genetic background (RB1/TP53 co-loss) rather than by the therapy itself.

Diagram: Convergent Neuroendocrine Transdifferentiation Pathway

Squamous Transdifferentiation

A further documented transdifferentiation pattern occurs in a subset of EGFR-mutant lung adenocarcinomas, which can instead transform to squamous cell carcinoma histology following targeted therapy, representing an alternative transdifferentiation trajectory distinct from the neuroendocrine route and suggesting that multiple alternative lineage identities may be reachable from a common permissive dedifferentiated intermediate state, with the specific resulting lineage determined by additional, less fully characterized factors beyond RB1/TP53 status alone.

Clinical Significance and Detection Challenges

Because transdifferentiated tumors retain the original driver mutation while acquiring a fundamentally different histology and treatment sensitivity profile, timely recognition through repeat biopsy at the point of clinical treatment resistance is critical for appropriate treatment adjustment, since continued treatment targeted at the original lineage dependency (androgen receptor or EGFR pathway inhibition) is expected to be ineffective against the transdifferentiated tumor, whereas therapies appropriate to the new lineage (small-cell lung cancer- or neuroendocrine-directed chemotherapy regimens) may restore some degree of treatment response.

Experimental Assessment

Transdifferentiation is studied using paired pre- and post-resistance biopsy comparison with histological and immunohistochemical confirmation of lineage switching alongside genetic confirmation (shared driver mutation) that the transdifferentiated tumor is clonally derived from the original tumor rather than a separate malignancy, genetically engineered mouse models incorporating the relevant permissive tumor suppressor losses to directly test the sufficiency of RB1/TP53 co-loss for enabling transdifferentiation under therapy pressure, and single-cell profiling of tumors captured during the transition to characterize intermediate transdifferentiation states.